NCT03366519

Brief Summary

Pulmonary Embolism (PE) is a frequent disease, the third cause of cardiovascular death after stroke and myocardial infarction. According to European guidelines of European Society of Cardiology (ESC) and of European Respiratory Society (ERS), the prognostic stratification of PE severity is mandatory as soon as PE is diagnosed. This stratification includes the hemodynamic status, and specific tools : the assessment of the sPESI score, and the evaluation of PE's impact on right ventricle (RV) : increased biomarkers (troponin, BNP) and right ventricle/left ventricle (RV/LV) ratio. the RV/LV ration may be evaluated ideally by transthoracic echo (TTE), or by CT scan. Unfortunately, only 10% of patients with PE are evaluated with TTE by a cardiologist in the initial time of PE diagnosis. Hence, the CT scan is the most frequent way to assess RV/LV ratio. However, CT is not possible for all patients (patients with contra-indication) or may have difficulties to provide a clear assessment because of technical issues. Then, there is a need for morphological evaluation of RV as soon as PE is diagnosed, in every clinical setting. The improvement in technologies allowed the development of clinical echography (CE) in emergency departments. CE is already available, non-invasive, less expansive, and may be a good way to assess RV/LV ratio in patients with PE diagnosed in emergency departments. The investigators propose a prospective, multicenter study to assess the sensitivity of CE in patients with PE, compared to CT scan to detect RV/LV ≥0.9.

Trial Health

15
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Nov 2018

Shorter than P25 for all trials

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 21, 2017

Completed
17 days until next milestone

First Posted

Study publicly available on registry

December 8, 2017

Completed
11 months until next milestone

Study Start

First participant enrolled

November 1, 2018

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2018

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2019

Completed
Last Updated

April 4, 2019

Status Verified

March 1, 2019

Enrollment Period

1 month

First QC Date

November 21, 2017

Last Update Submit

April 2, 2019

Conditions

Keywords

Embolism, Pulmonaryechocardiographyemergencyprognosis

Outcome Measures

Primary Outcomes (1)

  • Patients with a measure RV/LV ratio ≥ 0.9 on clinical echography (CE) and CT Scan

    Sensitivity of clinical echography (CE) to CT Scan to detect an increased RV/LV ratio above 0.9.

    day 1

Secondary Outcomes (3)

  • Patients with a measure RV/LV ratio < 0.9 on clinical echography (CE) and CT Scan

    day 1

  • Patients with abnormal inferior vena cava.

    day 30

  • death

    day 30

Study Arms (1)

patients with pulmonary embolism

patients with pulmonary embolism confirmed by tomography scan in emergency department

Procedure: clinical echography (CE)

Interventions

clinical echography (CE) is performed in the first 24 hours following the diagnosis of PE, in emergency unit

patients with pulmonary embolism

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

All patients with a PE confirmed in emergency unit

You may qualify if:

  • Adult patients with pulmonary embolism confirmed
  • Simplified Pulmonary Embolism Severity Index (sPESI) ≥ 1

You may not qualify if:

  • Contra-indication to CT scanner
  • Patients with high-risk pulmonary embolism (shock, hypotension)
  • Simplified Pulmonary Embolism Severity Index (sPESI) =0

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Pulmonary EmbolismEmergencies

Condition Hierarchy (Ancestors)

Lung DiseasesRespiratory Tract DiseasesEmbolismEmbolism and ThrombosisVascular DiseasesCardiovascular DiseasesDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Alain Viallon, MD PhD

    Centre Hospitalier Universitaire de Saint Etienne

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 21, 2017

First Posted

December 8, 2017

Study Start

November 1, 2018

Primary Completion

December 1, 2018

Study Completion

January 1, 2019

Last Updated

April 4, 2019

Record last verified: 2019-03

Data Sharing

IPD Sharing
Will not share